Like any company, Pfizer (NYSE: PFE) faces some risks that could give investors pause. Patents for several of the company’s drugs begin to expire after 2025. There’s uncertainty about recurring revenue for Pfizer’s COVID-19 vaccine after the pandemic ends.
But there are also factors that make Pfizer attractive despite those risks. In this Motley Fool Live video recorded on Aug. 4, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why investors should consider buying Pfizer stock right now.